重组人生长激素治疗特发性矮小症效果的影响因素分析

Influencing factors of efficacy of recombinant human growth hormone therapy on idiopathic short stature

目的探究重组人生长激素治疗特发性矮小症的效果及其影响因素。方法回顾性抽取2021年8月至2023年8月郑州大学第一附属医院收治的特发性矮小症患儿92例为研究对象,均采用重组人生长激素注射液治疗,分析治疗效果及其影响因素。结果治疗有效74例,无效18例,有效率为80.43%(74/92)。多因素Logistic回归分析结果显示,治疗前生长速度<4.46 cm/年、治疗前骨龄<8.04岁、治疗前身高标准差积分<-2.51、治疗前骨碱性磷酸酶<92.24μg/L、有母体孕期合并症为影响特发性矮小症患儿疗效的危险因素(P<0.05)。结论重组人生长激素注射液能有效治疗特发性矮小症患儿,但疗效受治疗前生长速率、治疗前骨龄成熟度、治疗前身高标准差积分、治疗前骨碱性磷酸酶、有母体孕期合并症等因素影响。

ObjectiveTo investigate the clinical efficacy of recombinant human growth hormone therapy on idiopathic short stature and its influencing factors.MethodsNinety-two children with idiopathic short stature admitted to the First Affiliated Hospital of Zhengzhou University from August 2021 to August 2023 were retrospectively selected as the research objects.They all underwent recombinant human growth hormone therapy.The treatment efficacy and influencing factors were analyzed.ResultsIn the study,74 cases had effective outcome,and 18 cases had ineffective outcome,with an effective rate of 80.43%(74/92).The results of multivariate logistic regression analysis showed that growth rate before treatment<4.46 cm/year,bone age before treatment<8.04 years,height standard deviation score before treatment<-2.51,bone alkaline phosphatase before treatment<92.24μg/L,and maternal comorbidities were risk factors for the efficacy in the treatment of children with idiopathic short stature(P<0.05).ConclusionsRecombinant human growth hormone therapy has an ideal effect in the treatment of children with idiopathic short stature,whereas the efficacy of treatment can be affected by the growth rate,skeletal maturity,height standard deviation score,bone alkaline phosphatase,and presence of maternal comorbidities before treatment.